Remarkably, the impact of SLIT2 inhibition on angiogenesis and the augmentation of T cell response surpasses the outcomes achieved by previously explored therapeutic approaches targeting the TAM component within the GBM TME [139]. The gene discussed is SLIT2; the disease is glioblastoma.